ARTICLE | Company News
JenKem, 3SBio deal
October 13, 2014 7:00 AM UTC
JenKem granted 3SBio exclusive rights in China to develop and commercialize PEG-irinotecan, a long-acting polymer-drug conjugate that inhibits topoisomerase I (TOP1). 3SBio expects to submit an IND ...